OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2021-12-31-accounts

The Macular Disease Society operating under the name The Macular Society

Report and Accounts 31 December 2021

Macular Society Report and Accounts for year ended 31 December 2021

Contents Patrons and Advisers 3-4
Report of the Trustees 11
Report of the Auditors 50
Statement of Financial Activities 58
Balance Sheet 59
Statement of Cash Flows 60
Notes to the Accounts 61
Appendix A – Research Committee 81

2 Macular Society

Macular Society Report and Accounts for year ended 31 December 2021

President

Timothy ffytche, LVO, FRCS, FRCOphth (from 9 February 2021)

Patrons

Henry Blofeld OBE *

Gemma Craven *

Gwyneth Dickinson MBE *

Patricia Greene *

Vince Hill*

Maggie Norden

Zac Shaw *

The symbol * indicates visual impairment.

Macular Society 3

Macular Society Report and Accounts for year ended 31 December 2021

Auditors

Clifford Fry & Co, St. Mary’s House, Netherhampton, Salisbury, Wiltshire SP2 8PU

Bankers Barclays Bank Plc, South West London Corporate Banking, 1 The Causeway, Teddington, Middlesex TW11 0HB Legal Furley Page LLP, Advisers Admiral’s Offices, Main Gate Road, The Historic Dockyard, Chatham, Kent ME4 4TZ

Investment Rathbone Investment Management Ltd, Managers 8 Finsbury Circus, Finsbury, London EC2M 7AZ

Registered Crown Chambers, South Street, Office (and actual office Andover, Hampshire SP10 2BN address)

Contact Tel 01264 350 551 – Office information Tel 0300 3030 111 – Advice & Information Email info@macularsociety.org

4 Macular Society

Macular Society Report and Accounts for year ended 31 December 2021

The Directors of the Macular Disease Society submit their annual report and audited financial statements for the year ended 31 December 2021. The Directors of the Company are also Trustees of the Society and are known collectively as the Council. This report includes as separate statements, the Directors’ Report and the Directors’ Strategic Report, as required by the Companies Act 2006 (Strategic Report and Directors’ Report) Regulations 2013, given in their capacities as Directors/Trustees. The term Trustee is used throughout this report.

History and Objectives

The Society was founded as a membership body in 1987 by a group of patients and medical professionals.

They recognised that macular disease was a growing public health problem. However, there was little awareness among the general public about the disease the impact of which was too often underestimated by medical professionals.

Consequently patients received little emotional or practical support to cope with a devastating condition. Policy makers did not prioritise eye care and little research funding was allocated to finding treatments.

Macular disease is now the biggest cause of sight loss in the developed world and the third biggest globally. In the UK it is responsible for as much registered sight loss as all the other conditions combined: being the dominant reason for registration in children, working age people and older people. As such it is a major public health challenge.

Macular Society 5

Macular Society Report and Accounts

for year ended 31 December 2021

To meet the challenge, the Society’s objectives are to support medical research to find a cure for macular disease, and to provide information, advice and other services to improve the lives of people living with macular disease. We summarise these aims in this way:

Beating Macular Disease

Our vision:

An end to macular disease.

Our mission:

Beating macular disease with world class research and the best advice and support.

Our strategic aims:

Our values

Everyone at the Macular Society aims to live its values in all we do.

We will Beat Macular Disease by

6 Macular Society

Macular Society Report and Accounts for year ended 31 December 2021

We are Ambitious.

We will Beat Macular Disease.

We are committed to be brave in our actions to make the progress that people need.

We will fundraise to find a cure, empower our team, be progressive yet supportive and dedicated in our belief...

...to Beat Macular Disease.

We are Supportive and Caring.

We provide a caring, approachable, and supportive environment for each member, supporter, volunteer, and all members of our team.

We act with empathy in all that we do. We listen to each other and we all work together...

...to Beat Macular Disease.

We have Integrity and we act honestly.

We are trusted for our supportive, open and collaborative approach, our professional expertise and our dedication to be the best we can be to do more...

...to Beat Macular Disease.

Macular Society 7

Macular Society Report and Accounts

for year ended 31 December 2021

Structure, Governance and Management

The Society is a Company Limited by Guarantee, without Share Capital, incorporated on 13 October 1987 and registered as a Charity on 10 December 1990.

At the end of 2021, the Society had 15,304 members – 12,972 voting members and 2,332 six months free trial members.

There were 410 peer support groups at the end of 2021. The majority, 359, operate under the Society’s charity number. Fifty one groups are ‘affiliated’, operating under the auspices of other organisations such as local societies for visually impaired people.

Each group that operates under our charity number is required to submit an annual financial return at the year-end. These returns are combined into the Society’s own financial statements.

Owing to the continuation of lockdowns and social isolation guidance, few groups met. However c. 7,000 people remained registered as group members.

The majority of groups have used teleconferencing facilities provided by the Society to keep in touch with their members or have done so on a one-to-one basis.

8 Macular Society

Macular Society Report and Accounts for year ended 31 December 2021

The Society is granted exemption from Income Tax under s.505 ICTA 1988 and exemption from Capital Gains Tax under s.256 TCGA 1992. The Charity and Company number are shown on the back page of this document.

The Company was established under a Memorandum of Association which confirmed the objects and powers of the Company and is governed under its Articles of Association.

Under the Articles, the Trustees are appointed by the Council to serve a maximum period of six years, with a reappointment requirement after three years. The exception to this is the Hon. Treasurer who may serve up to three consecutive three-year terms.

Vacancies for Trustees are advertised widely in Sideview (the members’ quarterly magazine) and elsewhere.

Applications are reviewed by the Governance and Appointments Panel. Selected candidates are invited to a meeting with the Chief Executive for a briefing on the Society and discussion of the role and responsibilities of Trustees. Trustee training takes place by means of the initial briefing and study workshops.

The Council of Trustees meets four times a year. In addition to the top-level decision making undertaken by Council, preparatory work takes place in committees comprising a combination of Trustees, Society members, salaried staff, and external advisers, as required.

Macular Society 9

Macular Society Report and Accounts for year ended 31 December 2021

These committees are:

• Finance and Fundraising

Reviews the annual budget, monitors financial and fundraising performance and provides risk management oversight.

• Research

Allocates research funding and monitors output from research projects.

• Governance and Appointments Panel

Oversees governance and appoints Trustees and key employees. Sets the remuneration of key management personnel.

• Ethics Committee

Reviews the Society’s policies and activities to make sure the organisation operates to the highest ethical standards.

• Public Policy and Government Affairs Advisory Group

Provides expert advice and guidance on the Society’s work to represent the views of patients to policy makers.

In all its activities, the Macular Society Trustees and staff pay due regard to the Charity Governance Code.

10 Macular Society

Trustees’ Report for year ended 31 December 2021

The Trustees present their report and the financial statements for the year ended 31 December 2021.

Trustees’ Responsibilities Statement

The Trustees are responsible for preparing the Strategic report, the Trustees report and the financial statements in accordance with applicable law and regulations.

Company law requires the Trustees to prepare financial statements for each financial year. Under that law the Trustees have elected to prepare the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’. Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the surplus or deficit of the Company for that year.

In preparing these financial statements, the Trustees are required to:

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Company’s transactions and disclose with reasonable accuracy at any time

Macular Society 11

Trustees Report for year ended 31 December 2021

the financial position of the Company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Results and Dividends

The surplus for the year, after taxation, amounted to £1,703k (2020 - £134k).

Trustees

The Trustees who served during the year were:

Cecilia Bufton BSc (Hons) MBA – Chair

Paul Ryb BA(Hons) * – Vice Chair

Alison Guthrie MCOptom – Vice Chair

Richard Piller FCA, CTA – Honorary Treasurer

William Best BSc (Hons) *

Tim ffytche LVO, FRCS, FRCOphth (resigned 9 February 2021)

Anna Fletcher LLB *

Dr Sheena George, FRCOphth

Robin Hamilton, FRCOphth

Charles Griffith ACII, CFA (appointed 11 May 2021, resigned

8 February 2022)

Frances Luff BA (Hons)

Anthony MacQuarrie M Ed, B Phil, DASEC, Cert Ed * (resigned 11 May 2021)

12 Macular Society

Trustees’ Report for year ended 31 December 2021

Patrick McGeough Eng MIIE (Mech), RAF Rtd * James Potter LLM *

Amanda Rowland LLB *

Sobha Sivaprasad, FRCOphth

Stephen Stacey MA, DPhil

Elaine Latham

Christopher Strutt (resigned 11 February 2022)

Catherine Yelf – Chief Executive and Company Secretary

Future Developments

Future developments are set out in detail on pages 14 to 43 in the Trustees’ Strategic Report. There are no going concern issues, which may affect the Company’s ability to continue its activities for the foreseeable future.

Disclosure in the Strategic report

The company has chosen in accordance with Companies Act 2006, s414c(11) to set out information required under sch7 to be disclosed in the Trustees report within the Trustees Strategic report.

Disclosure of information to auditors

Each of the persons who are Trustees at the time when this Trustees’ report is approved has confirmed that:

so far as the Trustee is aware, there is no relevant

Macular Society 13

Trustees’ Report for year ended 31 December 2021

information of which the Company’s auditors are unaware, and

the Trustee has taken all the steps that ought to have been taken as a Trustee in order to be aware of any relevant audit information and to establish that the Company’s auditors are aware of that information.

Post balance sheet events

The impact of COVID-19 and Brexit has been considered by the Trustees within their Strategic Report.

Auditors

The auditors, Clifford Fry & Co LLP, will be proposed for reappointment in accordance with section 485 of the Companies Act 2006.

Approved by the Council of Trustees on 10 May 2022.

Cecilia Bufton Chair of the Council Macular Society

14 Macular Society

Trustees’ Strategic Report for year ended 31 December 2021

Responsibilities of Trustees

Trustees responsibilities are set out in the Code of Conduct (‘The Code’) for Trustees. The principal duties are these:

Trustees must, with the help of the Chief Executive, formulate and review regularly the Society’s vision, values, and strategy as well as policies for their fulfilment.

With the assistance of the Chief Executive and appropriate professional advisers, Trustees must make sure that the Society complies with all regulatory and statutory requirements and must exercise overall control over the Society’s financial affairs. In addition to compliance with statutory requirements, Trustees should have a commitment to the development and implementation of good practice in charity operations and in good governance.

Trustees must make sure there is a clear understanding of the scope of authority delegated to the Chief Executive.

The Code also sets out the relationship between the staff and Trustees. It is the role of the Chief Executive to implement the Society’s vision, values and strategy through a combination of salaried staff and volunteers.

Assessment of Public Benefit

The Trustees have complied with the duty in Part 1 Chapter 1 s4 of the Charities Act 2011 to have due regard to public benefit guidance published by the Commission. The Trustees have had regard for the guidelines when reviewing the Society’s aims and objectives and in planning for future

Macular Society 15

Trustees’ Strategic Report for year ended 31 December 2021

activities. The public benefit of the charity is in finding a cure for macular disease, providing best advice and support for those living with the conditions and educating the public that ‘vision matters’.

The Trustees consider how planned activities will contribute to the aims and objectives they have set with the executive team. The Trustees consider that the Macular Society satisfies the public benefit test.

The day-to-day management of the Macular Society is led by the Chief Executive on agreed authority delegated by the Council of Trustees.

Financial Review

The financial statements show a surplus for the year of £1,703k (2020: £134k). Total funds at the year-end were £5,483k (2020: £3,780k).

The measures taken in 2020 to protect our financial position during the COVID-19 global pandemic were successful and our fundraising continued to be effective. As a result we felt confident in setting a deficit budget for 2021. The pandemic continued to have a significant impact on our plans in several income streams such as events and community fundraising, but many areas of our fundraising showed growth in the year. There are still delays in HM Courts and Tribunals Service, meaning that some legacy gifts have not been paid to us. However, a large bequest of £1.5m ensured that overall legacy income was in excess of that forecast.

16 Macular Society

Trustees’ Strategic Report for year ended 31 December 2021

Reserves Policy

Unrestricted reserves at the year-end amounted to £3,758k (2020: £2,946k). Each year the Trustees consider the financial and other risks associated with our income and expenditure streams. Our policy is to hold unrestricted reserves representing a minimum of four months of our costs budgeted for 2022. This amounts to £1,692k for 2022 and represents the costs of executing an orderly winding up of the Society if such were required. In addition, we aim to hold a level of reserves necessary to protect the Society from variances outside our immediate control. We also seek to ensure that our planned expenditure over the coming years can be covered by reserves while our Great Fundraising income generation plans come fully to fruition and our fundraising investment sees the forecast returns

The impact of COVID-19 will be felt into 2022 and, coupled with high inflation rates and a still unquantifiable impact of the UK leaving the EU, will continue to require a cautious approach to spending. For these reasons we have retained the designated fund in anticipation of continuing exceptional and unpredictable circumstances.

Investment Policy

We invest funds not required in the short term with Rathbone Investment Management Ltd (Rathbones). The Portfolio performance is reviewed regularly by the Finance Committee, which reports to Council. Rathbones are instructed not to invest in tobacco stocks owing to the strong evidential link between smoking and macular disease. There is a strong Environmental, Social and Governance thread to the investments in the Portfolio, in line with Rathbones’ own approach in these areas.

Macular Society 17

Trustees’ Strategic Report for year ended 31 December 2021

The total fund started the year at £1,410k and ended the year at £1,579k. During the year COVID-19 had an impact on capital growth and investment returns, especially in quarter two. Performance finished strongly, delivering investment income of £33k. Overall, this result was in line with the investment objectives set when Rathbones were engaged as Investment Managers in 2019.

The Society’s policy is to invest remaining cash reserves in bank deposits or similar instruments. Of the £5,273k at the year-end (excluding cash held by local groups), £321k was on deposit with Nationwide, £401k with NatWest and £1,000k with Lloyds TSB. The remaining cash is held with Barclays. Interest income for the year amounted to £1k (2020: £3k).

Research Grants

Research grants are awarded by Trustees on the recommendations of the Research Committee which is comprised of clinical and research experts in relevant fields and is chaired by an independent Chair.

In May 2021 the Chair, James Bainbridge, Professor of Retinal Studies at University College London and Consultant Ophthalmologist at Moorfields Eye Hospital, stood down as his term of office had ended.

He was succeeded by Luminita Paraoan, PhD (Gen), PhD (Mol Biol), FARVO, FRSB, FHEA, Professor of Molecular Cell Biology and Leader of the Ocular Molecular Biology and Mechanisms of Disease Group, Eye and Vision Science, Faculty of Health and Life Sciences at the University of Liverpool.

18 Macular Society

Trustees’ Strategic Report for year ended 31 December 2021

The full Committee membership can be found at Appendix A.

The Committee invites applications for funding of research projects within research area priorities set by the Trustees.

Applications are independently peer-reviewed and assessed by the Committee. Selected projects are formally approved by the Council.

The progress of projects (which may last up to three years) is monitored by the Research Committee with periodic reports to Council.

Executive Team

The executive team comprises:

Catherine Yelf , Chief Executive

Emma Malcolm , Director of Fundraising and Marketing Stephen Scowcroft , Director of Services (from May 2021) Karen Noble , Head of Finance

Rebecca Ward , Head of HR

John McKay , Head of IT and Data Insight

Their pay is reviewed annually by the Governance and Appointments Panel and is set having regard to market information in respect of charities of equivalent size with head office operations located outside London.

Macular Society 19

Trustees’ Strategic Report for year ended 31 December 2021

Risk Assessment

The Trustees have reviewed the major risks that the Society faces and believe the Society has sufficient resources to cope with any foreseeable adverse conditions. The major risks that might impact the Society have been assessed and we are satisfied with the actions taken to mitigate exposure to these risks.

The most significant of these risks are:

20 Macular Society

Trustees’ Strategic Report for year ended 31 December 2021

Our Approach to Fundraising

Everyone who supports us may be assured that we comply with the regulatory standards for fundraising. We are registered with the Fundraising Regulator and are committed to the Fundraising Promise and adherence to the Code of Fundraising Practice. Several members of the fundraising team, including the Director, are Institute of Fundraising members.

It has cost us £4,174k to provide our services and fund our research programme, all of which came from fundraised income.

Our fundraising includes our membership programme, encouraging donations and gifts in Wills, running events working with trusts and corporates and operating a weekly lottery and raffle. (All profits from the weekly lottery go to the Macular Society. Of the £359,814 received in ticket sales from January to December 2021, 20% was spent on expenses, 20% on prizes and 60% was used to fund our important work. From the proceeds of all tickets sold in the two raffles during 2021: 12% was spent on expenses, 13% on prizes and 75% was used to fund our important work). We have an annual Groups’ Research Appeal. Via this Appeal, we invite groups to undertake fundraising and to secure donations for a specific research project.

We monitor and evaluate the impact of internal and external factors on fundraising performance against our strategy and our wider aims and objectives. We review and adapt/amend timescales, expenditure and income targets and the content of fundraising plans designed to achieve our objectives. We seek a wide range of feedback

Macular Society 21

Trustees’ Strategic Report for year ended 31 December 2021

and also benchmark against the market and our key performance indicators.

During 2021, our fundraising increased, most notably from Legacy income, as the HM Courts and Tribunals delays began to improve.

We also launched our first regular giving campaign ‘Fund a Cure’ via Face to Face fundraising.

We work with carefully selected third parties to raise money to Beat Macular Disease, including professional fundraisers. We work closely with all our third party suppliers to make sure they deliver a high quality experience for our supporters through training, monitoring and contractual arrangements. We also carry out mystery shopping and have robust systems in place for receiving and addressing feedback, which we are always pleased to receive.

Our website carries our complaints policy for the public and explains clearly how an individual may complain. We received three complaints in 2021 (2020: nine) from 31million fundraising contact points.

We responded to all complaints within five days. Complaints are dealt with in line with our fundraising complaints policy. The most serious complaints are escalated to our Chief Executive and Trustees so they may review our activities in the light of the complaint. We report the number of complaints we have received to the Fundraising Regulator.

22 Macular Society

Trustees’ Strategic Report for year ended 31 December 2021

We are registered with the Fundraising Preference Service so that individuals are able to opt out from receiving fundraising communications from us. We actioned 11 requests from this Service in 2021.

In addition to our general fundraising policy, we have an agreed operating procedure to protect vulnerable people. The policy is based on the framework recommended by the Direct Marketing Association and developed by the DMA’s Vulnerable Taskforce Committee. Our staff are trained in how to put this policy into practice with all our contacts. The full policy can be found on our website. https://www.macularsociety.org/about/policies/vunerable-people-policy/

Environmental responsibility

The Macular Society’s aim is to deliver the overall objectives of the organisation while also developing, maintaining and delivering an environmental and social responsibility impact.

The Macular Society accepts that some of our operations have a detrimental effect on both the local and global environment and is committed to reducing them further.

We have a role to play and a duty of care to staff, volunteers, members and wider society with regard to climate and environmental change. There is an increasing expectation from all of these stakeholders that we are doing what we can, as well as encouraging our wider audience through leading by example.

Macular Society 23

Trustees’ Strategic Report for year ended 31 December 2021

We will have choices as to what we do in order to get the balance right between achieving our mission while also limiting our environmental impact and being sustainable.

A group of staff, known as the Green Group, has been established to help the Macular Society to develop policy and practice to reduce our carbon footprint.

Beating Macular Disease by finding a cure 2021

Key Evaluation Question:

How effectively is the Macular Society supporting research and progressing us towards cures for macular disease?

The amount of research grant funding awarded by the Society each year continues to rise. The UK has some of the finest academic and clinical research scientists in the world in macular disease and the Society’s funding in this under-resourced area is critical. The knowledge generated by Macular Society-funded research is key to developing future new therapies.

We operate a two-stage application process starting with an outline application that must be accompanied by a lay summary. Applicants shortlisted by the Research Committee submit a full application which is peer reviewed before being assessed again by the Committee. The Committee’s recommendations are considered by the full Council for approval.

24 Beating Macular Disease by finding a cure

Trustees’ Strategic Report for year ended 31 December 2021

Research Committee members may serve up to two terms of three years. Two Macular Society Trustees are members of the Committee and represent the Council.

We received 27 grant applications for our 2021 funding programme. 26% were considered ‘fundable’.

In July 2021 we launched the new ‘seed corn’ grant programme and received 11 applications, three of which were considered fundable.

Our seed corn funding grants are for up to £25,000 for one year projects designed to acquire data to support promising projects to the next stage of funding.

Three projects were approved in 2021 for funding in 2022.

Some of the new 2020 projects had recruitment related delays due to the pandemic, which meant that they were not able to start until early 2021. However the projects already underway were able to continue their research through the lockdown period at the start of the year, so no further significant delays were incurred.

The new 2021 projects were able to start on time but one project is slightly delayed because the lead researcher is in the process of changing universities.

Macular Society 25

Trustees’ Strategic Report for year ended 31 December 2021

The following research grants, to the value of £1,219,671 were awarded in 2021:

Project grants:

Professor Andrew Webster, University College London 2 years £109,432

Identifying genetic factors responsible for adverse clinical outcomes of ABCA4 mutation in macular disease; interrogation of large genomic datasets

Professor Andrew Dick, University of Bristol 3 years £243,732

Manipulating immune regulators that maintain retinal pigment epithelial health and metabolism as a therapeutic strategy for age-related macular degeneration (AMD)

Dr Jamie Ellingford, University of Manchester 3 years £249,950

METR-GT: The Manchester Eye Tissue Repository Genome-Transcriptome Project

Professor Luminita Paraoan, University of Liverpool 3 years £220,670

Elucidating the role of mitochondrial dynamics and endoplasmic reticulum-mitochondrial communication in ageing retinal pigmented epithelium: towards new therapeutic interventions for macular disease

26 Beating Macular Disease by finding a cure

Trustees’ Strategic Report

for year ended 31 December 2021

Professor Dulcie Mulholland, University of Surrey 3 years £196,338

Novel homoisoflavonoids for the inhibition of ocular angiogenesis

PhD Studentships:

Dr Linda Troeberg, University of East Anglia 3 years £99,573

Does aberrant extracellular trafficking cause both age-related and genetic forms of macular degeneration?

Dr Keziah Latham, Anglia Ruskin University 3 years £99,976

Assessing the costs and benefits of innovative low vision aids

In addition:

The Society contributes to the research environment in multiple ways in addition to our grant funding programme.

Macular Society 27

Trustees’ Strategic Report for year ended 31 December 2021

This ‘hybrid’ event (part in-person, part online) was chaired by Professor Alistair Denniston and Professor Pearse Keane.

researchers. The Macular Society applied to this fund and will receive funds in 2022 Our CEO, who is a member of the AMRC Executive Board, has also been involved in discussions with senior NHS leaders on the use of patient data in research.

28 Beating Macular Disease by finding a cure

Trustees’ Strategic Report for year ended 31 December 2021

Action Against AMD

Action Against AMD (AAAMD) was created as a specialised charity collaboration between the Macular Society, Blind Veterans UK, Sight Scotland and Sight Scotland Veterans. It is focused on tackling AMD as early as possible, specifically to identify a potential new therapy that may prevent early AMD developing into late-stage disease and taking it to early stage clinical trials by 2028/9.

We believe this is the most rational way to address the forecast increase in the incidence of AMD in an ageing population. AAAMD’s strategy is to:

Despite the challenges caused by COVID, AAAMD made strong progress in 2021.

AAAMD and the University of Birmingham continued their pharmaco-epidemiology collaboration to analyse anonymised medical records from 20+ million UK patients. The aim is to identify drugs which might be protective against AMD. Several possibilities have been found and AAAMD and the University will next work to validate the

Macular Society 29

Trustees’ Strategic Report for year ended 31 December 2021

results. If this is successful, AAAMD will aim to take them into clinical trials. AAAMD is also engaged in discussions with an US biotech company to secure access to a novel and potent antioxidant to be tested against AMD.

AAAMD’s CEO sits on the steering committee of the Scottish Collaborative Optometry-Ophthalmology Network e-research (SCONe) project based at the University of Edinburgh. This project aims to study images of the retina to improve care and support research.

In a separate project, AAAMD has also secured an initial investment in principle of £1m from two Scottish charities to progress a project to access community-level eye scans. AAAMD entered discussions with two other organisations (one UK, one US) with a view to securing further investment.

The aim of this project is to acquire and analyse eye scans obtain from the patients of community optometrists. These patients have early or no disease and such scans are important in being able to identify the first stages of AMD. AAAMD will take this work forward within a fully-owned trading subsidiary called Foresight.

To further strengthen the offering of Foresight’s ophthalmic data and to promote the need for focus on eye research, AAAMD has been working closely with the UK government’s Our Future Health (OFH) initiative. This project is to genotype five million Britons in the next three years. OFH is chaired by Prof Sir John Bell and AAAMD is

30 Beating Macular Disease by finding a cure

Trustees’ Strategic Report for year ended 31 December 2021

one of 16 charities endorsing the initiative (alongside much-larger organisations such as Cancer Research UK, the British Heart Foundation and Alzheimer’s Research UK).

In addition to endorsing, AAAMD’s CEO Dr Wen Hwa Lee has worked with OFH successfully to include sight loss in their launch statement and to ensure eye disease is investigated as part of this project. https://ourfuturehealth.org.uk/the-uks-largest-everhealth-research-programme-to-transform-theprevention-detection-and-treatment-of-diseases/

Looking ahead

In November the Trustees met to discuss how the Society might diversify its research funding as our income grows. We are presently a ‘response-mode’ funder of academic research. Our 10 year research strategy, published in 2020 identified a need to expand the ways in which we fund research.

The meeting introduced a range of possible new avenues to explore. These included creating new funding streams for more directed or commissioned research, technology development, business accelerator grants, ‘action’ research in the community and even direct investment in promising early stage commercial start-up companies. Trustees agreed to investigate these options further in 2022.

Macular Society 31

Trustees’ Strategic Report for year ended 31 December 2021

Beating Macular Disease by finding a cure – 2022 targets

32 Beating Macular Disease by finding a cure

Trustees’ Strategic Report for year ended 31 December 2021

Beating Macular Disease with the best advice and support 2021

Key Evaluation Question:

Is the Macular Society effectively supporting people with macular disease?

Supporting more people

2021 was a remarkably successful year for the Society’s services in spite of the continuing pandemic. Using the lessons learnt during 2020 we continued to expand our digital services delivery in our aim to double the number of people we support, or our ‘reach’, between 2019 and 2023. In some services we mean doubling the number of individuals supported. In others we mean the number of occasions on which we provide support.

For example, we know how many individuals are referred to the counselling service and we count those rather than the number of counselling sessions given. However, we historically have not identified how many individuals call the Advice and Information service more than once in year so, for that service, we count the number of times the service provides advice. We take that as a proxy measure to indicate whether we are reaching more people. We now count attendance figures for virtual group meetings and webinars as they are significant ‘in person’ events, albeit delivered online or by teleconference.

Beating Macular Disease with the best advice and support 33

Trustees’ Strategic Report for year ended 31 December 2021

While this does not provide complete data, we have been consistent in reporting in this way for several years and believe that, as long as the process is transparent, it is an adequate means of demonstrating growth in our service delivery. We will refine this process over time.

Throughout the second year of lockdown our staff, once again, worked with great energy, dedication and professionalism to stay in touch with, and motivate, our volunteers and provide more services to as many people as possible.

As a result we won two awards for our response to the pandemic:

34 Beating Macular Disease with the best advice and support

Trustees’ Strategic Report for year ended 31 December 2021

Our support groups

Only a handful of our local support groups met in person during 2021 and then only in the second half of the year when restrictions were relaxed.

In spite of the long shutdown of groups they have shown great resilience. At the year-end 410 groups were still operating in a viable way. This compares with 430 before the start of the pandemic and 420 at the start of 2021. This is a result of dedicated work by staff to maintain the groups and also the extraordinary efforts and loyalty of the many hundreds of volunteers who have been determined to keep their groups intact. We congratulate them and humbly thank them all.

Virtual communities

In the absence of face to face meetings, we have accelerated the growth of virtual ‘communities’. Most groups continued to meet, usually by teleconference. In the course of the year the regional team facilitated 2,790 hour-long calls – the equivalent of 372 working days. The calls had 19,801 attendees. Among the teleconferences were the Winter Warmer calls, held monthly for the second year between October and February. The calls are in the evenings and are designed to offer entertainment and companionship. These alone attracted 601 attendees.

Many local support groups now want to maintain these alongside their physical meetings. The virtual groups are accessible by people, who would otherwise not be able to

Macular Society 35

Trustees’ Strategic Report for year ended 31 December 2021

benefit from this sort of peer support, perhaps because of mobility or transport problems or because they just do not have a group near them.

Video conferencing is also gaining ground, even with older people and we will support the expansion of the webinars to include other practical and emotional educational or personal experience topics

We continued to hold our ‘Virtual Clinic’ webinars on a range of topics. The Chief Executive hosted monthly events aimed at an AMD audience. Colin Daniels the Working Age and Young People (WAYP) Services Manager hosted monthly events for people affected by other macular conditions and on subjects that affect people of working age. The webinars are available online after the live event.

The webinars attracted a total of 16,191 attendees, either at the live events or as viewers of the recordings.

We held our annual conference online again. As in 2020, the morning was devoted to macular dystrophies and other macular conditions such as diabetic macular oedema and the afternoon to AMD. These sessions focused on science and research progress. We added a parallel stream that ran in both the morning and the afternoon called Macular and Me. This strand was carefully devised for people wholly new to macular disease, their family and friends and people keen to learn more about living with a macular condition. The feedback from all these strands was extremely positive. My Macular and Me will be the overarching title of our webinar series in 2022.

36 Beating Macular Disease with the best advice and support

Trustees’ Strategic Report for year ended 31 December 2021

Working age and young people

Face to face groups for younger people are moving away from physical meetings. Where they are working well we will continue to support them. However, we do not plan to develop new communities in any particular locality or region. Macular conditions are relatively rare in young people and so face to face meetings in a locality are often poorly attended.

The emphasis is now on building communities around specific conditions or topics. We have established communities on diabetic macular oedema and myopic maculopathy. We will also focus on topics such as going into or staying in employment.

The WAYP Facebook page continues to grow its membership and is a vibrant and dynamic community itself. It now has 700 members and has seen over 3,700 interactions where people are asking and answering questions, supporting others with advice and experience.

We have directly supported 138 individuals with specific employment and benefit related advice, information, mentoring and support and continued to build this community focussing on providing condition specific content and employment related topics.

In order to support parents and teachers of children affected by macular conditions, we have refreshed and republished a suite of materials for teachers of visually impaired children and launched them at the start of the autumn term.

Macular Society 37

Trustees’ Strategic Report for year ended 31 December 2021

Peer support and volunteer strategy review

In common with many charities, we have found that attendance at face to face peer support groups has been falling in recent years and it has become increasingly difficult to recruit volunteers. Some of our volunteers felt the demands of running a formal group were too great and others felt that, although they wished to stand down from their role with the group, they were not able to as there was no one to take over from them.

We conducted a survey of our volunteers in 2020. It demonstrated that that volunteering is an enjoyable experience (94.2%) for our volunteers and that they feel valued and appreciated by the Society (91.2%), which results them in wanting to recommend it to others (97.8%). However, the review highlighted that there is more that we can and should be doing.

In 2021 we completed a wide ranging review of our peer support services and our volunteering.

Peer support groups

We concluded that our groups are changing organically and we need to change to support them. It is more helpful now to regard our ‘groups’ as ‘communities’ so that we can embrace a more flexible and loosely organised model. It is clear that a formal, perhaps bureaucratic, model is less popular than it was. The structure of a committee, comprised of a Chair, Treasurer and Secretary was originally designed to share the workload of running a group among several people and not just one volunteer.

38 Beating Macular Disease with the best advice and support

Trustees’ Strategic Report for year ended 31 December 2021

Many groups adopted the formalities of taking minutes of meetings and holding an AGM for the election of officers. We encouraged groups to sign our constitution and to have a bank account if they were handling anything more than petty cash. These structures, originally intended and seen as supportive, are now viewed as a burden by many volunteers.

Many groups meet in community venues but there is an increasing demand for groups of people to meet in public spaces such as cafes and bars which are often more flexible, accessible, cost effective and do not have the burden of needing to be managed.

The existing model for groups assumes that they form part of our ‘educational’ services by having formal talks at meetings. Many newer groups are focused on the social interaction and peer support. And of course formal ‘talks’ are not possible in public spaces.

Although our groups have had multiple purposes, providing social, educational, practical and psychological support, what emerged from the review, and from the wider sector, is that the groups primarily provide a social focus, with information and support secondary. The review showed that we need to be clear in the purpose and focus of a group or ‘community’ so they achieve what we and the participants need them to do. We intend to focus on the social aspects of these communities in future. This makes clear what the group primarily is for and where it sits in the wider peer support services we provide. With this approach, signposting to other services becomes key.

Macular Society 39

Trustees’ Strategic Report for year ended 31 December 2021

This reinforces that the group does not stand alone and is part of a wider organisation that is beating macular disease and making things happen. Covid-19 has also highlighted that the growing area of concern and greatest need is on tackling isolation.

Supporting volunteers

Our volunteers are critical to the success of many of our services. We are grateful to and humbled by the commitment, dedication and generosity of our volunteers. We recognise the importance of good recruitment, training and support for our volunteers.

Having reviewed our volunteer strategy we have set out our vision for our volunteering and set our priorities. The vision is that through a supportive and empowering volunteer experience, our volunteers will make the greatest positive impact for everyone affected by macular disease.

The three key priority areas are:

40 Beating Macular Disease with the best advice and support

Trustees’ Strategic Report for year ended 31 December 2021

In order to achieve and deliver on the priority areas we:

We communicated with our volunteers in a variety of ways; through specific volunteer updates, newsletters and messages to thank, recognise volunteers and ensure they feel part of a wider team and organisation that is beating macular disease.

National and telephone services

Many of our services are designed to be delivered remotely and these have continued uninterrupted throughout the pandemic.

Macular Society 41

Trustees’ Strategic Report for year ended 31 December 2021

infection control measures have led to a streamlining of clinic appointments with less time available for wider conversations between patients and clinicians and, frequently, a complete ban on the display of patient information leaflets.

Effective support

We measure the effectiveness and impact of our services by surveying a representative group of 300 service users each year. The results show a significant increase in appreciation scores on 2020 in nearly every area.

42 Beating Macular Disease with the best advice and support

Trustees’ Strategic Report for year ended 31 December 2021

Beating Macular Disease with the best advice and support – 2022 targets

Macular Society 43

Trustees’ Strategic Report for year ended 31 December 2021

Vision matters – Beating Macular Disease by improving eye health 2021

Key Evaluation Question:

Is the general population aware of macular disease and the Macular Society?

The rise in conditions such as age-related macular degeneration means that, in the NHS, ophthalmology is now the biggest outpatient specialty with around 11m outpatient appointments in 2021. Even before the

pandemic, health and care services in many parts of the country were struggling to cope with demand. This had led to unnecessary sight loss for patients who suffered delays to their treatment.

Sadly, there is no doubt that the COVID-19 pandemic has had a significant impact on the nation’s eye health.

We have worked to influence the NHS Restoration and Transformation work to make sure that the whole needs of people with macular disease are considered as the NHS reconfigures its services. There are many welcome innovations developing in the reshaped delivery of care. However, we remain concerned that the streamlining of the pathways will mean that there is no resource for the holistic care of the patient; their emotional and practical needs beyond the eye clinic and the medical treatment itself. As part of this we significantly increased our focus on influencing public policy on eye health. A Public Policy and Government Affairs Advisory Group of Trustees helped develop our approach.

44 Beating Macular Disease by improving eye health

Trustees’ Strategic Report for year ended 31 December 2021

We partnered with the pharmaceutical company Roche and the research charity Fight for Sight on a joint parliamentary campaign called The Eyes Have It. The campaign included the development of a website and eye disease simulator headset as well as a very successful Westminster Eye Health Day which was attended by around 50 Parliamentarians.

We jointly campaigned for a National Clinical Director for Eye Health in England to provide the leadership that we believe is necessary to transform eye health and protect the interests of patients. In the autumn it was confirmed that such a role would be created.

The campaign also achieved:

We continued to work with national bodies, both statutory and voluntary to improve eye care. These included the Clinical Council for Eye Health Commissioning and the UK Ophthalmology Alliance.

Macular Society 45

Trustees’ Strategic Report for year ended 31 December 2021

In October 2021 we launched our Macular Risk Checker, which was advertised via Facebook between 14 October and 3 December.

Based on a product from the Macular Disease Foundation Australia, the risk checker is available through our website and takes the form of a short quiz. Relevant content, based on the answers given to the quiz is provided and based on the potential risk of developing AMD. The user is given the option to stay in touch with us.

The risk checker has enabled us make ourselves relevant to new audiences (including the ‘at risk’ group), to engage with them, to stay in touch to help them look after their sight and keep them informed about progress in research that may make the difference to them in the future. In addition, this gives us an opportunity to grow our supporter base and help generate incremental income for research and support services so that future generations do not have to live with the devastating effects of macular disease and can be supported right now.

This all contributes to delivering our Vision Matters strategic pillar. Almost 33,000 people checked their risk between 14 October and 31 December. Ten per cent opted to continue receiving communications from us. Over October and November the Risk Checker doubled the traffic to our website.

46 Beating Macular Disease by improving eye health

Trustees’ Strategic Report for year ended 31 December 2021

Vision matters – Beating Macular Disease – by improving eye health 2022 targets

Macular Society 47

Trustees’ Strategic Report for year ended 31 December 2021

The Trustees wish to express their thanks to all our donors and supporters without whom none of our work is possible.

Approved by the Council of Trustees on 10 May 2022

Cecilia Bufton, Chair of the Council, Macular Society

48 Beating Macular Disease by improving eye health

Finding a cure

We will beat macular disease

Best advice and support

Improving eye health

Macular Society 49

Independent Auditors’ Report to the Members of the Macular Disease Society

Opinion

We have audited the financial statements of The Macular Disease Society (the ‘Company’) for the year ended 31 December 2021, which comprise the Statement of Financial Activities (incorporating an income and expenditure account), the Balance sheet, the Statement of cash flows and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further

50 Macular Society

Independent Auditors’ Report to the Members of the Macular Disease Society

described in the Auditors’ responsibilities for the audit of the financial statements section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council’s Ethical Standard and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusion relating to going concern

In auditing the financial statements, we have concluded that the Trustees use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Company’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

Macular Society 51

Independent Auditors’ Report

to the Members of the Macular Disease Society

Other information

The other information comprises the information included in the Annual Report other than the financial statements and our Auditors’ report thereon. The Trustees are responsible for the other information contained within the Annual Report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinion on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

52 Macular Society

Independent Auditors’ Report to the Members of the Macular Disease Society

financial statements are prepared is consistent with the financial statements; and

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the Company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic report or the Trustees’ report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

Macular Society 53

Independent Auditors’ Report to the Members of the Macular Disease Society

Responsibilities of Trustees

As explained more fully in the Trustees’ responsibilities statement set out on page 11, the Trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so.

Auditors’ responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditors’ report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence

54 Macular Society

Independent Auditors’ Report to the Members of the Macular Disease Society

the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

We gained an understanding of the legal and regulatory framework applicable to the company and the industry in which it operates, including obtaining details on how they identify and comply with laws and regulations and whether they were aware of any non-compliance, how they detect and respond to the risks of fraud and whether they have knowledge of any actual, suspected or alleged fraud and finally the controls they have in order to mitigate risks of fraud or non-compliance with laws and regulations.

We designed audit procedures to respond to the risk, recognising that the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, intentional misrepresentations.

As a result of these procedures, we considered the opportunities and incentives that may exist within the

Macular Society 55

Independent Auditors’ Report to the Members of the Macular Disease Society

organisation for fraud and identified the greatest potential for fraud in the following area: revenue and profit recognition.

We focussed on laws and regulations which could give rise to a material misstatement in the financial statements, including, but not limited to, the Companies Act 2006, Charities SORP (FRS102) and UK tax legislation.

Our tests included agreeing the financial statement disclosures to underlying supporting documentation, performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud, reviewing minutes of meetings and enquiries with management.

We did not identify any key audit matters relating to irregularities, including fraud. As in all our audits, we also addressed the risk of management override of internal controls, including testing journals and evaluating whether there was evidence of bias by the Trustees that represented a risk of material misstatement due to fraud.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council’s website at: www.frc.org.uk/auditors responsibilities . This description forms part of our Auditors’ report.

56 Macular Society

Independent Auditors’ Report to the Members of the Macular Disease Society

Use of our report

This report is made solely to the Company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Company’s members those matters we are required to state to them in an Auditors’ report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company’s members, as a body, for our audit work, for this report, or for the opinions we have formed.

S M Allenby FCA (Senior statutory auditor)

for and on behalf of Clifford Fry & Co LLP

St Mary’s House Netherhampton Salisbury Wiltshire SP2 8PU

10 May 2022

Macular Society 57

Statement of Financial Activities

(incorporating an income and expenditure account). For the year ended 31 December 2021

£’000 £’000 £’000 £’000
Unrestricted Restricted Total Total
Funds Funds 2021 2020
Notes
Income from:
Donations and legacies 2(1) 4,004 2,743 6,747 4,182
Charitable activities 2(2) - 723 723 996
Other trading activities 2(3) 65 58 123 112
Investment income & interest 2(4) 34
 - 34 31
Total income 4,103 3,524 7,627 5,321
Expenditure on:
Raising funds 3(1) 1,885 - 1,885 1,422
Charitable activities 3(2) 1,541 2,633 4,174 3,845
Total expenditure 3,426 2,633 6,059 5,267
Net income before Gains/(losses)
on investments 677 891 1,568 54
Net gains/(losses) on
investments 8 135 - 135 80
Net income/(expenditure)
& net movement in funds 812 891 1,703 134
Reconciliation of funds
Total funds brought forward 2,946 834 3,780 3,646
Total funds carried forward 3,758 1,725
 5,483 3,780

There are no recognised gains or losses other than those disclosed above. All income and expenditure derives from continuing activities.

58 Macular Society

Balance Sheet

As of 31 December 2021


Notes
Fixed assets:
Tangible assets
7
Investments
8
Current assets:
Stocks
9
Debtors
10
Cash and bank balances
Cash held by local groups
Current liabilities:
Creditors: amounts falling
due within one year
11
Net current assets
Total assets less current
liabilities
Creditors: amounts due
after more than one year 12
Net assets
16
Funds
Unrestricted funds
15
Designated funds
15
Restricted funds
14
Total funds		 2021
£’000
3
732
5,273
360
6,368
1,814		 2020
£’000
£’000
45
1,579
1,624
6
317
3,581
365
4,269
1,449
4,554
6,178
695
5,483
2,758
1,000
1,725
5,483		 £’000
32
1,410
1,442
2,820
4,262
482
3,780
1,946
1,000
834
3,780

The notes on pages 61 to 80 form part of these accounts.

The financial statements were approved and authorised for issue by the Council of Trustees and were signed on its behalf on 10 May 2022.

Cecilia Bufton, Chair of the Council

Richard Piller FCA, CTA, Hon. Treasurer

Macular Society 59

The Macular Disease company registered number: 2177039

Statement of Cash Flows

For the year ended 31 December 2021

2021 2020
£’000 £’000
Cash flows from operating activities
Net income for the year
 1,703 134
Adjustments for:
Depreciation of fixed assets
 34
 34
(Gain)/loss on disposals of investments (135) (80)
Decrease/(increase) in debtors (415) 122
Decrease/(increase) in stock
 3 1
Increase/(decrease) in creditors
 578 572
Investment income and interest (34) (31)
Net cash from operating activities
 1,734 752
Cash flows from investing activities
Proceeds from sale of investments
 221 333
Purchases of investments (281) (344)
Purchases of fixed assets (47) (20)
Investment income 33 28
Interest received 1 3
Decrease in cash held for investment 26 -
Net cash from investing activities (47) 0
Net increase/(decrease) in cash and cash equivalents 1,687 752
Cash and cash equivalents at beginning of year 3,946 3, 194
Cash and cash equivalents at end of year 5,633 3,946
Analysis of cash and cash equivalents
Cash in hand 5,633 3,946
Total cash and cash equivalents 5,633 3,946
60Macular Society

Notes to the accounts

For the year ended 31 December 2021

1. Accounting policies

The Macular Society is a private charitable company, limited by guarantee and incorporated in England, which is a public benefit entity under FRS102.

(FRS 102) and the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 (as amended).

(a) Basis of preparation

The net income of the Society arises solely from continuing activities. The accounts have been prepared on the accruals basis and combine the financial activities of the Society and local Groups. They have been prepared in £ sterling and rounded to the nearest thousand.

(b) Accounting convention

The accounts have been prepared under the historical cost convention and in accordance with the applicable United Kingdom Accounting Standards, the Charities Statement of Recommended Practice

(c) Going Concern

After reviewing the Charitable Company’s forecasts and projections, the Trustees have a reasonable expectation that the Company has adequate resources to continue its activities for the foreseeable future. The Company, therefore, continues to adopt the going concern basis in preparing its financial statements.

(d) Tangible Fixed Assets

Tangible Fixed Assets are stated at historical cost less accumulated depreciation. Historical cost includes expenditure directly

Macular Society 61

Notes to the accounts

For the year ended 31 December 2021

attributable to bringing the assets into use.

(e) Depreciation of Tangible

Fixed Assets

Depreciation is charged on a straight line basis by reference to the expected useful lives of the assets concerned. The rates used are 33 for IT 1/3% and film equipment and 20% for office equipment. Fixed assets purchased by local Groups are written off in the year of purchase.

(f) Investments

Investments are stated at market value. Unrealised gains and losses are recognised in the statement of financial activities.

(g) Stocks

Stocks are valued at the lower of cost and estimated realisable value.

(h) Legacies

Legacies are accounted for when it is probable that they will be received and the amount can be reliably ascertained.

(i) Debtors

Debtors are measured at amortised cost less any impairment.

(j) Creditors

Creditors and provisions are recognised where the Charitable Company has a present obligation resulting from past events that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts which may be due.

62 Macular Society

Notes to the accounts

For the year ended 31 December 2021

(k) Cash and Cash Equivalents

at amortised cost comprise cash at bank and in hand, together with trade and other debtors. Financial liabilities held at amortised cost comprise bank loans and overdrafts, trade and other creditors.

Cash is represented by cash in hand and deposits with financial institutions payable without penalty on notice of not more than 24 hours.

Cash equivalents are highly liquid investments that mature in not more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

Investments, including bonds, held as part of an investment portfolio are held at fair value at the Balance Sheet date, with gains and losses being recognised within income and expenditure.

(l) Financial Instruments

The Charitable Company has financial assets and financial liabilities of a kind which qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at amortised cost using the effective interest method. Financial assets held

(m) Donated services

Donated services are included at estimated valuation.

(n) Volunteers

The Charitable Company has in the region of 1,400 volunteers. The financial value which these volunteers make is not incorporated

Macular Society 63

Notes to the accounts

For the year ended 31 December 2021

within these financial statements.

(o) Local Groups

In order to reflect correctly the stewardship of the Charitable Company over activities of its local support groups, their results are included in the SOFA and their cash balances at the year end are included in the Balance Sheet as restricted funds. The amounts have been incorporated based on returns received by the Charitable Company by 21 February 2021.

(p) Grants received

Where related to performance and specific deliverables, grants are accounted for when the Society earns the right to the consideration. UK Government assistance for COVID-19 is accounted for in the period in which it is received.

(q) Expenditure

Expenditure includes irrecoverable VAT.

(r) Research grants Unconditional research grants payable in future years are accrued for in the year awarded.

(s) Unrestricted Funds

Unrestricted Funds comprise income received without restriction as to its use.

(t) Designated Funds

Designated Funds comprise funds set aside by the Trustees out of Unrestricted Funds to create a COVID Recovery Fund to address exceptional and unpredictable circumstances from COVID-19, particularly around legacy and trust income.

(u) Restricted Funds

Restricted Funds comprise income received for the purposes specified by the

64 Macular Society

Notes to the accounts

For the year ended 31 December 2021

donor. Expenditure, which meets these criteria, is applied to the related Fund.

(v) Resources expended Resources expended are allocated to the particular activity where the cost relates directly to that activity. Payroll and support costs are apportioned to these activities on the bases set out in Notes 4 and 5. Restructuring and redundancy costs are recognised when the Company has an obligation to pay the benefits and they can be measured reliably.

(x) Expenditure on raising funds Expenditure on raising funds relates to the costs of attracting income and those incurred in trading activities that raise funds.

(w) Income tax recoverable in relation to donations received under Gift Aid is recognised at the time of production of the claim and allocated to the appropriate income stream.

Macular Society 65

Notes to the accounts

For the year ended 31 December 2021

2021
£’000
2. Analysis of incoming resources
(1) Donations and legacies
Donations, appeals and unrestricted grants
1,464
Membership subscriptions
283
Fundraising events
701
Legacies (Note 18)
4,299
6,747
£3,166k of the 2020 income was unrestricted and £1,016k restricted.
(2) Income from charitable activities
Grants for specified charitable activities
672
Job Retention Scheme Grant
-
Other – donated services
51
723
(3) Income from other activities
Local group income (restricted)
58
Trading income (unrestricted)
65
123

(4) Income from Investments and Interest
Interest received
1
Investment Income
33
34
The income for 2020 was all unrestricted.		 2020
£’000
1,968
270
513
1,431
4,182
911
36
49
996
48
64
112
3
28
31

66 Macular Society

Notes to the accounts

For the year ended 31 December 2021


3. Analysis of resources expended
(1) Costs of raising funds (unrestricted)
Employee remuneration (Note 5)
Support costs (Note 4)
Direct costs
Trading costs
Investment management costs		 2021
2020
£’000
£’000
759
593
156
161
930
625
28
33
12
10
1,885
1,422
(2) Charitable activities
Publications
Educational information
Advice & Information
& Counselling
Groups & Volunteers
Low Vision
Conferences
Research
Support to professionals
Local group activities		 2021
£’000
Direct
costs
£’000
Staff
costs
£’000
(Note 5)
Support
costs
£’000
(Note 4)
80
12
3
95
180
147
28
355
151
198
41
390
42
885
179
1,106
93
212
42
347
14
20
4
38
1,411
306
62
1,779
1
-
-
1
63
-
-
63
2,035
1,780
359
4,174		 2020
£’000
89
362
385
1,203
256
31
1,440
42
37
3,845

2020 charitable expenditure was charged as to £2,288k to restricted reserves and £1,557k to unrestricted.

Macular Society 67

Notes to the accounts

For the year ended 31 December 2021

4. Support costs
Rent and rates
Postage and office supplies
Telephone and IT
Depreciation
Recruitment
Bank charges
Governance
Other expenses		 2021
£’000
79
37
143
44
43
24
27
118
515		 2020
£’000
86
36
133
34
10
27
22
79
427

The support costs allocated to charitable activities have been allocated pro rata to the apportionment of staff costs allocated to those activities. The resulting allocation is shown in Note 3(2). Governance costs include the audit fee and taxation return fee totalling £12,000 (2020: £8,500).

5. Employee remuneration

The average number of full and part-time employees in the year was 74 (2020:73). The average number of employees calculated on a full-time equivalent basis, analysed by function was:

full-time equivalent basis, analysed by function was:
Management, governance and administration
Customer care and membership administration
Fundraising
Group development & volunteer coordination
Advice & Information and treatment advocacy
Low vision
Research
Education and awareness
Sideview and Digest		 2021
6
5
18
15
5
5
2
8
1
65		 2020
6
4
17
15
5
5
2
8
1
63

68 Macular Society

Notes to the accounts

For the year ended 31 December 2021

2021
 2020
£’000
 £’000
Salaries 2,210 2,213
National insurance 208 210
Pension costs 121 122
2,539 2,545

The number of employees whose emoluments*, as defined for taxation purposes amounted to over £60,000 in the year and to whom retirement benefits are accruing under money purchase pension schemes are:

2021 2020
Number Number
£60,000-£70,000 1 1
£70,000-£80,000 1 2
£80,000-£90,000 1 -
3 3

The total emoluments paid to the three key managers amounted to £202,000 (2020: 3 key managers £234,000)

*Emoluments for these purposes exclude pension contributions

The cost of staff that are involved in specific activities has been allocated to those activities; the balance of the payroll has then been allocated pro rata to the direct cost allocation. The central finance raising payroll costs have been allocated to specific activities pro rata to the funds raised for those activities.

Cost of fundraising
Cost of charitable activities		 2021
£’000
759
1,780
2,539		 593
1,952
2020
£’000
2,545

The payroll costs allocated to individual charitable activities is as set out in Note 3(2).

Included here (2020) are Restructuring and Redundancy costs of £101,159.

Macular Society 69

For the year ended 31 December 2021

Notes to the accounts

6. Pension scheme

The charity operates a defined contribution pension scheme. The pension charge for the year £121k (2020: £122k) represents contributions payable by the Company to the scheme. These costs are allocated on the basis of head-count of staff within each category of expenditure. Contributions totalling NIL (2020: £21,246) were payable to schemes at the year-end and are included in Creditors.

7. Tangible fixed assets

7. Tangible fixed assets
IT & flm
equipment		 Offce
equipment		 Total
£’000 £’000 £’000
Cost:
As at 1 January 2021 140 29 169
Additions 47 - 47
Disposals (89) - -(89)
As at 31 December 2021 98 29 127
Depreciation:
As at 1 January 2021 115 22 137
Charge for year 31 3 34
Disposals (89) -
 (89)
As at 31 December 2021 57 25 82
Net book amounts:
As at 31 December 2021 41 4 45
As at 31 December 2020 25 7 32

70 Macular Society

Notes to the accounts

For the year ended 31 December 2021

8. Investments
Market value as at 1 January 2021
Acquisitions at cost*

Disposals at carrying value

Net realised gains

Net unrealised gains

Total investments at market value at 31 December 2021
Cash held for investment
Total investments
Total investments at market value
Total investments at historical cost
Revaluation unrealised gain

Investments are further analysed as follows:
Listed equities (UK £478k, Overseas £465k)

Listed fixed interest and index linked
Investments (UK £317k, Overseas £89k)

Other investments

Cash held for investments

 2021
£’000
1,343
281

(221)

58

77

1,538

41

1,579

1,579

1,394

185
943
406
189
41
1,579		 2020
£’000
1,066
530
(333)
36
44
1,343
67
1,410
1,410
1,316
94
841
364
138
67
1,410

*Acquisitions include donated shares valued at £13,125 (2020:NIL)

Macular Society 71

Notes to the accounts

For the year ended 31 December 2021

9. Stockscomprise diaries & cards for sale
10. Debtors & prepayments
Legacies (Note 18)
Gift aid
Prepayments
Other debtors
11. Creditors & accruals: amounts falling due within one year
Research grants committed not yet paid
Trade creditors
Accruals & other payables
Taxation and Social Security
12. Creditors: amounts falling due
after more than one year
Research grants committed not yet paid

Accruals and other payables

 2021
£’000
3
580
51
101
-
732
1,446
228
134
6
1,814
615

80

695
 2020
£’000
6
207
41
69
-
317
1,163
107
111
68
1,449
412
70
482

72 Macular Society

Notes to the accounts

For the year ended 31 December 2021

13. Analysis of research grants

Grant payments have been made or accrued during the year for the following research projects, all of which are with universities and other medical institutions:

Macular Society 73

Notes to the accounts

For the year ended 31 December 2021

13. Analysis of research grants (continued)

Charged to reserves
Restricted
£’000
Unrestricted
£’000
University of East Anglia
100
University of Liverpool
221
University of Surrey
196
University of Manchester
250
University College London
109
Anglia Ruskin University
100
University of Bristol
244
Moorfields
5
AAAMD
74
Salary, support and other costs
480
Total charge to reserves
1,779
Total research expenditure – Note 3(2)
1,779
£’000
Research grants committed but not yet paid
b/f 1 January 2021
1,575
Grants directly paid in the year to institutions
732
Research grants committed but not yet paid
c/f 31 December 2021
(246)
2,061
* Excludes attributed indirect costs calculated in
accordance with the apportionment in Note 1(t)		 Charged to reserves
Restricted
£’000
Unrestricted
£’000
University of East Anglia
100
University of Liverpool
221
University of Surrey
196
University of Manchester
250
University College London
109
Anglia Ruskin University
100
University of Bristol
244
Moorfields
5
AAAMD
74
Salary, support and other costs
480
Total charge to reserves
1,779
Total research expenditure – Note 3(2)
1,779
£’000
Research grants committed but not yet paid
b/f 1 January 2021
1,575
Grants directly paid in the year to institutions
732
Research grants committed but not yet paid
c/f 31 December 2021
(246)
2,061
* Excludes attributed indirect costs calculated in
accordance with the apportionment in Note 1(t)		 Charged to reserves
Restricted
£’000
Unrestricted
£’000
University of East Anglia
100
University of Liverpool
221
University of Surrey
196
University of Manchester
250
University College London
109
Anglia Ruskin University
100
University of Bristol
244
Moorfields
5
AAAMD
74
Salary, support and other costs
480
Total charge to reserves
1,779
Total research expenditure – Note 3(2)
1,779
£’000
Research grants committed but not yet paid
b/f 1 January 2021
1,575
Grants directly paid in the year to institutions
732
Research grants committed but not yet paid
c/f 31 December 2021
(246)
2,061
* Excludes attributed indirect costs calculated in
accordance with the apportionment in Note 1(t)
1,779





1,779
£’000
1,575
732
(246)
2,061

74 Macular Society

Notes to the accounts

For the year ended 31 December 2021

14. Restricted funds

The Society’s Restricted funds, into which are paid amounts received with a specific request that the income should be used to fund specified activities, comprise:

As at Movement in year Movement in year As at
1 Jan 2021 Income Expenses 31 Dec 2021
£’000 £’000 £’000 £’000
Research 405 2,739 (1,779) 1,365
National Lottery Community Fund
– People & Communities		 34 - (34) -
Groups & Services - 562 (562) -
Counselling 30 9 (39) -
Local Groups 365 58 (63) 360
National Lottery Community Fund
for practical and emotional - 156 (156) -
support for people with sight loss
834 3,524 (2,633) 1,725

Macular Society 75

Notes to the accounts

For the year ended 31 December 2021

14. Restricted funds (continued)

Restricted income includes:

76 Macular Society

Notes to the accounts

For the year ended 31 December 2021

15. Unrestricted and designated funds

As at
1 Jan 2021
£’000
Income
£’000
Expenses
£’000
Transfer
£’000
31
Unrestricted
1,946
4,238
3,426
-

Designated
1,000
-
-
-

2,946
4,238
3,426
-
 As at
Dec 2021
£’000
2,758
1,000
3,758

The Company transferred (2021:NIL) (2020:£1,000k) from its Unrestricted funds to a Designated fund, to create a COVID-19 Recovery Fund in anticipation of any exceptional and unpredictable circumstances from COVID-19 particularly in relation to Legacy and Trust income.

16. Analysis of net assets between funds

Unrestricted Designated Restricted Total
funds funds funds funds
£’000 £’000 £’000 £’000
Fixed assets & Investments 1,624 - - 1,624
Net assets 1,134 1,000 1,725 3,859
2,758 1,000 1,725 5,483

17. Trustee remuneration

The Trustees received no remuneration during the year (2020: nil).

During the year 6 Trustees (2020: 3) were reimbursed for travel and out of pocket expenses amounting to £1,096 (2020: £445).

Macular Society 77

Notes to the accounts

For the year ended 31 December 2021

18. Legacies

Legacies of an estimated £1,920,000 (2020: £892,700) have been excluded from income as the criteria for recognition had not been met.

19. Commitments

As at 31 December 2021 the Society had the following annual office rent commitments under non-cancellable operating leases:

Payable within one year
Payable from one year to five years		 2021
£’000
66
61
127		 2020
£’000
66
127
193

20. Analysis of changes in net debt

As at
1 Jan 2021
£’000		 As at
1 Jan 2021
£’000		 Cash
fows
£’000		 As at
31 Dec 2021
£’000
Cash and cash equivalents
Cash
 3,946
 1,687 5,633
Borrowings
Debts due in under 1 year
 (1,449)
 (365) (1,814)
Debts due after 1 year
 (482)
 (213) (695)
(1,931)
 (578) (2,509)
Total
 2,015
 1,109 3,124
78Macular Society

Notes to the accounts

For the year ended 31 December 2021

21. Share capital and members’ guarantees

The Company is limited by guarantee and has no share capital. Each member, whilst a member or within 12 months of ceasing membership, undertakes to contribute on a winding up such amount, not exceeding £1, as may be required.

22. Ultimate controlling party

The Society was controlled throughout the current and previous year by the Board of Trustees.

23. Financial Instruments

At the balance sheet date the Company held financial assets at fair value of £5,633k (2020: £3,946k).

24. Related Party Transactions

During the year a grant payment was made to Action Against AMD amounting to £74,000 (2020: £22,000).

The Macular Society and Action Against AMD are related by virtue of Catherine Yelf (CEO) being a Trustee of Action Against AMD, together with the CEOs of the other founding charities plus three independent Trustees. No balance was owing to AAAMD at the year end.

During the year Richard Piller, Honorary Treasurer and Trustee Director, acquired a minority shareholding in Okulo Ltd (also know as OKKO Health) a company with which the Macular Society transacts on an arms-length basis.

During 2020 it was agreed in principle to make a small grant of £5k to Professor Sobha Sivaprasad and others to fund a study of the impact of COVID-19 on the mental health of medical retina patients. This grant was paid in 2021. Professor Sivaprasad is a Trustee/Director of the Company.

During 2021 a grant of £220,670 was agreed to be paid to the University of Liverpool, with lead Professor Luminita Paraoan, to fund a study into new therapeutic interventions for macular disease.

There are ten members of our Research Committee: eight are distinguished academics from UK universities and two are Trustee Directors. The Committee

Macular Society 79

For the year ended 31 December 2021

Notes to the accounts

24. Related Party Transactions (continued)

is supported in its work by the Society’s Research Manager and a Research Officer. Grant applications for projects falling within research priorities set by the Trustees are invited annually and are reviewed by members of the Committee using specific assessment criteria.

In a second stage those applications that have been selected are peer-reviewed and then assessed by the Committee’s members with funding decisions being consensed in discussion. Committee members absent themselves from assessments in which they have a conflict of interest. The Committee’s final selection is approved formally by the Trustees. Each research project is monitored by the Committee’s officers with regular progress reports being submitted.

80 Macular Society

Appendix A Research Committee

Professor James Bainbridge

CHAIR (resigned April 2021) Professor of Retinal Studies, University College London and Consultant Ophthalmologist, Moorfields Eye Hospital

Professor Luminita Paraoan

CHAIR (appointed April 2021) Eye and Vision Science, Institute of Ageing and Chronic Disease, University of Liverpool

Professor Tariq Aslam

Professor of Ophthalmology and Interface Technologies, University of Manchester Consultant Ophthalmologist, Manchester Royal Eye Hospital

Bill Best

Macular Society Trustee and lay member

Dr Michael Crossland

Specialist Optometrist & Hon Senior Research Associate University College London and Moorfields Eye Hospital NHS Foundation Trust

Professor Alexander Foss

Consultant Ophthalmologist, Department of Ophthalmology, Nottingham University Hospitals NHS Trust

Dr Imre Lengyel

Senior Lecturer, Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Science, Queen’s University Belfast

Professor Astrid Limb

Professor of Retinal Biology and Therapeutics, Institute of Ophthalmology, University College London

Professor Tom Margrain

(resigned April 2021) Cardiff Centre for Vision Sciences, College of Biomedical and Life Sciences, Cardiff University

Professor Sobha Sivaprasad Macular Society trustee Medical Retina Consultant Ophthalmologist Moorfields Eye Hospital NHS Foundation Trust and Professor in Retinal Clinical Research University College London

Professor Adnan Tufail

Consultant Ophthalmologist, Moorfields Eye Hospital NHS Foundation Trust & Professor of Ophthalmolgy, University College London

Macular Society 81

Macular Society Crown Chambers, South Street, Andover, Hampshire SP10 2BN

Company Registered Numbers: England and Wales 2177039 Isle of Man: 005738F

Registered Charity Numbers: England and Wales: 1001198, Scotland: SC042015, Isle of Man: 1123